天士力(600535.SH):JS1-1-01片用於中重度抑鬱症治療獲美國FDA臨牀試驗批准
格隆匯8月2日丨天士力(600535.SH)公佈,日前,公司全資子公司天士力(北美)藥業有限公司(“北美藥業”)收到美國食品藥品監督管理局(“FDA”)關於同意化學藥品新藥JS1-1-01片用於中重度抑鬱症治療進行臨牀試驗的通知(IND編號:153206)。
JS1-1-01是公司自主研發的一種全新結構的 5-羥色胺–去甲腎上腺素–多巴胺三重再攝取抑制劑(SNDRIs),同時可促進腦源性神經營養因子(BDNF)的分泌,從而發揮抗抑鬱作用。公司已擁有涵蓋JS1-1-01 化合物、工藝、適應症及製劑的專利,其化合物專利已在中國、歐洲、美國、日本、韓國、澳大利亞等目標市場取得。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.